-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Intercept Pharmaceuticals, Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from 2016 to Q3 2023.
- Intercept Pharmaceuticals, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending September 30, 2023 was -$2.37M, a 101% decline year-over-year.
- Intercept Pharmaceuticals, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending September 30, 2023 was -$60.8M, a 130% decline year-over-year.
- Intercept Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was $216M.
- Intercept Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$91.8M, a 66.8% increase from 2020.
- Intercept Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2020 was -$276M, a 19.6% increase from 2019.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Growth (%)